The in vivo localization of anti-Wagner-osteogenic-sarcoma antibodies

Pressman, David; Korngold, Leonhard

doi:10.1002/1097-0142(195305)6:3<619::aid-cncr2820060319>3.0.co;2-y

Cited by 205 publications

(47 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Pressman (1966) noted that this localization occurred in the vascular bed of the target tissue. In other reports, there is a definite lag period before localization occurs, ranging from 36 h to more than 2 days.…”

Section: Methodsmentioning

confidence: 93%

Cellular localization of immunoglobulin within human malignant melanomata

Lewis¹,

Proctor²,

Thomson³

et al. 1976

Br J Cancer

View full text Add to dashboard Cite

Summary.-The presence of antibody in patients with malignant melanoma is well established if one examines the serum. In this report we have attempted to identify antibody within solid tumours showing that they are rarely present in any appreciable quantity on the surface of tumour cells but can be seen frequently on a number of different types of host cell within the tumours. This is discussed in the light of the role of antibody in the circulation and the possibility of antibody behaving as a blocking factor in vivo.

show abstract

Section: Methodsmentioning

confidence: 93%

Cellular localization of immunoglobulin within human malignant melanomata

Lewis¹,

Proctor²,

Thomson³

et al. 1976

Br J Cancer

View full text Add to dashboard Cite

show abstract

“…Similar results have been reported for unlabelled conjugates, measured by radioimmunoassay (Searle et al, 1986a). Distribution of W14A:CPG2 and F (ab')2: CPG2 conjugates Results of this experiment (after Pressman & Korngold, 1953) are presented in Table I, which includes control values for free W14A and its F (ab')2 fragment.…”

Section: Methodsmentioning

confidence: 99%

The potential of carboxypeptidase G2: antibody conjugates as anti-tumour agents. II. In vivo localising and clearance properties in a choriocarcinoma model

Melton

Searle²,

Sherwood³

et al. 1990

Br J Cancer

View full text Add to dashboard Cite

Summary The in vivo localising and clearance properties of conjugates of the folate-degrading enzyme carboxypeptidase G2 (CPG2) with anti-human chorionic gonadotrophin (W14A) were measured in nude mice bearing CC3 choriocarcinoma xenografts. Conjugates of W14A-F (ab')2 fragment coupled to CPG2 localised in tumour as effectively as native antibody alone but showed lower uptake in other major tissues. The clearance rates of conjugates prepared with intact antibody or F (ab')2 fragment were shown to be up to five-fold faster than for native antibody and two-fold compared to F (ab')2 fragment. Molecular weight analysis of residual conjugate in the blood showed that no degradation of conjugate to its component molecules occurred during circulation. It was concluded that F (ab')2: CPG2 conjugates offered the greatest potential for targeting applications.

show abstract

“…By nature, the technique requires the tumour cells to express an antigen that is unique to the neoplasm or is inaccessible in normal cells. The appealing concept of RIT was first described by Pressman and Korngold (1953). During the subsequent decades, various RIT radiopharmaceuticals were developed with advances in genetic engineering and chelating techniques.…”

Section: Molecular Targeting Radionuclide Therapy (Radioimmunotherapy)mentioning

confidence: 99%

Therapeutic radionuclides in nuclear medicine: current and future prospects

Yeong

Cheng

2014

J. Zhejiang Univ. Sci. B

158

115

View full text Add to dashboard Cite

Abstract:The potential use of radionuclides in therapy has been recognized for many decades. A number of radionuclides, such as iodine-131 ( 131 I), phosphorous-32 ( 32 P), strontium-90 ( 90 Sr), and yttrium-90 ( 90 Y), have been used successfully for the treatment of many benign and malignant disorders. Recently, the rapid growth of this branch of nuclear medicine has been stimulated by the introduction of a number of new radionuclides and radiopharmaceuticals for the treatment of metastatic bone pain and neuroendocrine and other malignant or non-malignant tumours. Today, the field of radionuclide therapy is enjoying an exciting phase and is poised for greater growth and development in the coming years. For example, in Asia, the high prevalence of thyroid and liver diseases has prompted many novel developments and clinical trials using targeted radionuclide therapy. This paper reviews the characteristics and clinical applications of the commonly available therapeutic radionuclides, as well as the problems and issues involved in translating novel radionuclides into clinical therapies.

show abstract

The in vivo localization of anti-Wagner-osteogenic-sarcoma antibodies

Cited by 205 publications

References 2 publications

Cellular localization of immunoglobulin within human malignant melanomata

Cellular localization of immunoglobulin within human malignant melanomata

The potential of carboxypeptidase G2: antibody conjugates as anti-tumour agents. II. In vivo localising and clearance properties in a choriocarcinoma model

Therapeutic radionuclides in nuclear medicine: current and future prospects

Contact Info

Product

Resources

About